What Is GLP-1? The Complete Beginner's Guide

A comprehensive introduction to GLP-1 — the hormone, the receptor agonist drugs, how they work for weight loss and diabetes, and what the future holds for this revolutionary drug class.

Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. GLP-1 receptor agonists are prescription medications. Always consult a qualified healthcare professional before starting, stopping, or modifying any medication.

GLP-1 receptor agonists have become the most talked-about drug class in modern medicine. Medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are producing weight loss results previously achievable only through bariatric surgery — 15-25% of total body weight in clinical trials. But beyond the headlines, many people are confused about what GLP-1 actually is, how these drugs work, and whether they're appropriate for them.

This guide explains GLP-1 from the ground up: what the hormone does naturally in your body, how pharmaceutical GLP-1 receptor agonists amplify those effects, the major medications available, and the practical considerations for anyone exploring this treatment. Whether you're researching for yourself or simply trying to understand the science behind the trend, this page gives you the complete picture.

For specific drug comparisons, dosing protocols, and related topics, explore our full GLP-1 hub.

GLP-1: The Natural Hormone

Glucagon-like peptide-1 (GLP-1) is a hormone your body already produces. When you eat, specialized cells called L-cells in the lining of your small intestine release GLP-1 into the bloodstream. It's part of the incretin system — a hormonal feedback loop that helps regulate blood sugar and appetite after meals.

Natural GLP-1 does several things simultaneously:

Stimulates insulin secretion from pancreatic beta cells — but only when blood sugar is elevated (glucose-dependent), which means it doesn't cause dangerous hypoglycemia on its own
Suppresses glucagon release from pancreatic alpha cells, reducing the liver's glucose output
Slows gastric emptying — food moves more slowly from the stomach to the intestines, extending feelings of fullness
Acts on the brain — GLP-1 receptors in the hypothalamus and brainstem reduce appetite and food reward signaling

The problem with natural GLP-1 is that it's extremely short-lived. The enzyme DPP-4 (dipeptidyl peptidase-4) breaks it down within 1-2 minutes of release. So while your body produces GLP-1 after every meal, the effect is brief and modest.

GLP-1 receptor agonist drugs solve this problem by mimicking GLP-1's structure in a way that resists DPP-4 degradation, allowing the effects to last for hours (liraglutide) or an entire week (semaglutide, tirzepatide). The result is dramatically amplified appetite suppression, blood sugar control, and — as it turns out — profound weight loss. For a deeper dive into the mechanism, see our how GLP-1 works page.

The Major GLP-1 Medications

Several GLP-1 receptor agonists are FDA-approved, each with different pharmacological profiles. The three most relevant for current discussion are:

Semaglutide (Ozempic / Wegovy)

Semaglutide is a pure GLP-1 receptor agonist developed by Novo Nordisk. Ozempic is the diabetes-approved formulation (up to 2mg/week); Wegovy is the obesity-approved formulation (2.4mg/week). Administered as a once-weekly subcutaneous injection. In the landmark STEP trials, Wegovy produced an average of 15-17% body weight loss over 68 weeks. It was also shown to reduce major adverse cardiovascular events (MACE) by 20% in the SELECT trial, leading to a cardiovascular indication. Rybelsus is an oral formulation of semaglutide for diabetes.

Tirzepatide (Mounjaro / Zepbound)

Tirzepatide is a dual GLP-1/GIP receptor agonist developed by Eli Lilly. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, providing dual incretin stimulation. In the SURMOUNT trials, tirzepatide produced average weight loss of 20-25% body weight — the highest of any non-surgical intervention. Mounjaro is the diabetes formulation; Zepbound is the obesity formulation. Once-weekly subcutaneous injection. See our semaglutide vs tirzepatide comparison.

Retatrutide (In Development)

Retatrutide is a triple agonist (GLP-1/GIP/glucagon receptor) currently in Phase 3 clinical trials by Eli Lilly. In Phase 2 trials, the highest dose produced approximately 24% body weight loss at 48 weeks — and the weight loss curve had not yet plateaued, suggesting even greater loss with longer treatment. If approved, it may become the most potent weight loss medication available. See our comparisons: semaglutide vs retatrutide and tirzepatide vs retatrutide.

Other GLP-1 Agents

Older GLP-1 agonists like liraglutide (Victoza/Saxenda — daily injection) and dulaglutide (Trulicity — weekly injection) remain available but produce less weight loss than semaglutide and tirzepatide. For fat loss specifically, some people also explore peptides like AOD-9604 and tesamorelin — see our comparisons: semaglutide vs AOD-9604 and AOD-9604 vs tesamorelin.

Who Are GLP-1 Medications For?

GLP-1 receptor agonists are FDA-approved for two primary indications:

Type 2 Diabetes

GLP-1 agonists were originally developed as diabetes medications. They improve blood sugar control through insulin stimulation, glucagon suppression, and slowed carbohydrate absorption. Semaglutide (Ozempic) and tirzepatide (Mounjaro) both reduce HbA1c (a measure of average blood sugar over 3 months) by 1.5-2.5 percentage points — among the most effective non-insulin diabetes treatments available. The weight loss they produce also improves insulin sensitivity, creating a virtuous cycle.

Obesity / Overweight with Comorbidities

Wegovy (semaglutide 2.4mg) and Zepbound (tirzepatide) are approved for chronic weight management in adults with a BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea). For more on using GLP-1 drugs for weight loss without diabetes, see our GLP-1 for weight loss in non-diabetics guide.

Cardiovascular Risk Reduction

Semaglutide (Wegovy) received an additional FDA indication for reducing cardiovascular risk in adults with established cardiovascular disease and overweight/obesity, based on the SELECT trial results showing a 20% reduction in major adverse cardiovascular events.

Off-Label and Emerging Uses

Research is actively exploring GLP-1 agonists for NAFLD/NASH (non-alcoholic fatty liver disease), PCOS (polycystic ovary syndrome), addiction (alcohol, nicotine — early data is promising), Alzheimer's disease (large-scale trials underway), and obstructive sleep apnea. The breadth of potential applications reflects the widespread distribution of GLP-1 receptors throughout the body.

Side Effects and Safety Considerations

GLP-1 agonists are generally well-tolerated, but they do have a characteristic side effect profile — primarily gastrointestinal. Understanding what to expect helps manage these effects effectively.

Common Side Effects (Affect 10-40% of Users)

Nausea — the most common side effect, especially during dose titration. Usually improves within 4-8 weeks.
Vomiting and diarrhea — related to slowed gastric emptying and GI adaptation.
Constipation — from delayed gastric motility.
Decreased appetite — this is the intended therapeutic effect, but some patients experience it as uncomfortably low appetite initially.
Injection site reactions — mild redness or itching at the injection site.

Less Common but Important Risks

Gallbladder disease — rapid weight loss increases gallstone risk regardless of the method. GLP-1 agonists may additionally slow gallbladder emptying.
Pancreatitis — rare but serious. Discontinue and seek medical attention for severe abdominal pain.
Muscle loss — significant weight loss from any cause includes some lean mass. This can be mitigated with resistance training and adequate protein. See our GLP-1 and muscle loss guide.

For a comprehensive side effect breakdown, see our GLP-1 side effects guide. The key to minimizing side effects is proper dose titration — starting at the lowest dose and increasing gradually over weeks. See our GLP-1 dosing and titration guide.

Practical Considerations — Cost, Access & What to Expect

Cost: Brand-name GLP-1 medications are expensive — list prices for Wegovy and Zepbound exceed $1,000/month in the US without insurance. Insurance coverage varies widely; many plans now cover these medications for obesity (not just diabetes) due to cardiovascular outcome data. Manufacturer savings programs and compounding pharmacies offer alternative access routes, though the FDA's position on compounded GLP-1 agonists is evolving. See our peptide legality guide for regulatory context.

Administration: Semaglutide and tirzepatide are administered as once-weekly subcutaneous injections using pre-filled auto-injector pens. The injection is simple — similar to insulin — and most patients self-administer at home after initial instruction. The needle is small (typically 32 gauge) and the injection is relatively painless. For injection technique, see our injection guide.

Timeline of effects: Appetite suppression begins within the first 1-2 weeks. Noticeable weight loss typically occurs within 4-8 weeks. The weight loss trajectory continues for 12-18 months before plateauing. Most clinical trials show maximum weight loss at 60-72 weeks.

Lifestyle factors matter: GLP-1 medications work best when combined with a high-protein diet (to preserve muscle mass), regular resistance training, and adequate hydration. They are not a replacement for healthy habits — they are a tool that makes healthy habits dramatically easier to maintain by reducing the constant hunger and cravings that sabotage most weight loss attempts.

Key Takeaways

GLP-1 is a natural gut hormone that regulates blood sugar, appetite, and gastric emptying. GLP-1 receptor agonist drugs amplify these effects by resisting enzymatic breakdown.
Semaglutide and tirzepatide are the current leading drugs, producing 15-25% body weight loss in clinical trials — approaching surgical outcomes.
Tirzepatide is a dual agonist (GLP-1 + GIP) and produces greater weight loss than semaglutide in head-to-head comparisons. Retatrutide (triple agonist) may surpass both.
Side effects are primarily GI (nausea, vomiting, constipation) and usually improve with proper dose titration over 4-8 weeks.
Muscle preservation requires effort — high protein intake (1g/lb lean mass) and resistance training are essential during GLP-1 therapy.
Explore our full GLP-1 hub for dosing guides, side effect management, and drug comparisons.

Frequently Asked Questions

What does GLP-1 stand for?

GLP-1 stands for glucagon-like peptide-1. It is an incretin hormone naturally produced by L-cells in the small intestine in response to food intake. The "glucagon-like" name comes from its structural similarity to glucagon, though its effects are largely opposite — GLP-1 stimulates insulin secretion, suppresses glucagon release, and slows gastric emptying. GLP-1 receptor agonist medications mimic and amplify these natural effects for therapeutic benefit in diabetes and obesity.

How do GLP-1 drugs cause weight loss?

GLP-1 receptor agonists cause weight loss through multiple mechanisms: they significantly reduce appetite by acting on hunger centers in the hypothalamus, they slow gastric emptying (making you feel full longer after meals), they reduce food reward signaling in the brain (decreasing cravings and the desire to eat), and they may increase energy expenditure modestly. The appetite suppression is the primary driver — most people on semaglutide or tirzepatide naturally eat 20-40% fewer calories without conscious effort.

What is the difference between semaglutide and tirzepatide?

Semaglutide (Ozempic/Wegovy) is a pure GLP-1 receptor agonist. Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1/GIP receptor agonist — it activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. In clinical trials, tirzepatide produced greater average weight loss than semaglutide (approximately 20-25% vs 15-17% body weight). Both are administered as weekly subcutaneous injections. See our detailed semaglutide vs tirzepatide comparison for a full breakdown.

Are GLP-1 medications safe?

GLP-1 receptor agonists have been extensively studied in clinical trials involving tens of thousands of participants. The most common side effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation — which typically improve over the first 4-8 weeks and can be minimized with gradual dose titration. Serious but rare risks include pancreatitis, gallbladder disease, and potential thyroid concerns (based on rodent studies). They are FDA-approved medications with a growing safety track record spanning over 15 years for the GLP-1 class.

Do you have to take GLP-1 medications forever?

Current evidence suggests that most people regain a significant portion of lost weight after discontinuing GLP-1 medications. The STEP 1 extension trial showed that participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year. This is because obesity involves persistent hormonal and neurological changes that do not fully reverse with weight loss. Many physicians view GLP-1 therapy as long-term management, similar to blood pressure medication, rather than a temporary intervention.

Who should not take GLP-1 medications?

GLP-1 receptor agonists are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), based on thyroid tumor findings in rodent studies. They should be used with caution in people with a history of pancreatitis, severe gastrointestinal disease, or gastroparesis. Pregnant or breastfeeding women should not use them. People with type 1 diabetes should not use GLP-1 agonists as a primary treatment. Always consult a physician for individual assessment.